海思科(002653.SZ):獲得創新藥HSK47977片IND申請受理通知書
格隆匯6月9日丨海思科(002653.SZ)公佈,公司於近日收到國家藥品監督管理局下發的HSK47977《受理通知書》。HSK47977片是公司自主研發,具有獨立知識產權的全球新口服小分子抗腫瘤藥物,擬用於淋巴瘤的治療。目前,全球同靶點藥物暫無臨牀數據公佈,國內也尚無同靶點藥物進入臨牀階段。
臨牀前研究結果顯示,HSK47977在體外展現出對人淋巴瘤細胞系明顯的增殖抑制作用,在體內異種移植模型中能有效抑制腫瘤生長,同時也表現出較強的靶點選擇性和理想的安全窗,是一款極具開發潛力的藥物,有望爲淋巴瘤患者提供一種新的治療選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.